Earticle

현재 위치 Home

GCAB01: HBV neutralizing human monoclonal antibody

첫 페이지 보기
  • 발행기관
    한국생물공학회 바로가기
  • 간행물
    한국생물공학회 학술대회 바로가기
  • 통권
    2008 춘계학술대회 및 국제심포지움 (2008.04)바로가기
  • 페이지
    pp.4-4
  • 저자
    Yong-Won Shin, Kyung-Hwan Ryoo, Ki-Tae Bong, Dong-Hyuck Seo, Kwang-Won Hong, Ki-Hwan Chang, Yong-Nam Shin, Sun-Jeong Oh, Bong-Sang Yoo, Jin-Seol Choi, Se-Ho Kim
  • 언어
    영어(ENG)
  • URL
    https://www.earticle.net/Article/A98514

※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.

원문정보

초록

영어
After 30 years of development, therapy with monoclonal antibodies has started to realize its promise. Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 20 monoclonal antibodies in the market
that have been approved by the FDA and over 150 in clinical developments.
Monoclonal antibodies may have a number of promising potential therapeutic applications in the treatment of cancer, autoimmune diseases, viral infections, asthma, and other diseases.
Hepatitis B virus (HBV) is one of the main pathogens of hepatitis and hepatocarcinoma.
Human plasma-derived Hepatitis B immune globulin (HBIG) is being used for prophylactic and liver transplantation currently. However, it is required to replace a HBIG with a recombinant one because of limited availability of human plasma with high anti-HBV antibody titer and possible contamination of human pathogens. In order to meet this requirements, we selected human antibody to the HBsAg from an anti-HBs Ab-enriched phage-display library and a Chinese hamster ovary (CHO) cell line, HBC7A, was established which produces a fully human IgG1 antibody against HBV. Mass production and purification processes were established and this mAb was characterized in terms of HBV neutralization and safety for the purpose of human trial for liver transplantation.

저자

  • Yong-Won Shin [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
  • Kyung-Hwan Ryoo [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
  • Ki-Tae Bong [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
  • Dong-Hyuck Seo [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
  • Kwang-Won Hong [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
  • Ki-Hwan Chang [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
  • Yong-Nam Shin [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
  • Sun-Jeong Oh [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
  • Bong-Sang Yoo [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
  • Jin-Seol Choi [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]
  • Se-Ho Kim [ Antibody Engineering Lab., Central Research Center, Green Cross Corp., ]

참고문헌

자료제공 : 네이버학술정보

간행물 정보

발행기관

  • 발행기관명
    한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
  • 설립연도
    1984
  • 분야
    공학>생물공학
  • 소개
    이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다 1. 생물공학 분야의 발전을 위한 연구 협력 2. 생물공학의 실용화를 촉진시키기 위한 산학 협동 3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최 4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간 5. 생물공학 발전을 위한 정책 건의 6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동

간행물

  • 간행물명
    한국생물공학회 학술대회
  • 간기
    반년간
  • 수록기간
    1985~2013
  • 십진분류
    KDC 476 DDC 576

이 권호 내 다른 논문 / 한국생물공학회 학술대회 2008 춘계학술대회 및 국제심포지움

    피인용수 : 0(자료제공 : 네이버학술정보)

    함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.

      페이지 저장